Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction.

"Declarations Ethics approval and consent to participateThe studies were approved by the regional ethics committees in Lund or Linköping, and were performed in compliance with EU guidelines and with the declaration of Helsinki. The SICU-2 study has been approved by the Swedish ethical review authority. All patients included in the study provided written informed consent. Competing interestsMichelle Chew is a member of the editorial board of Critical Care. Competing interests Michelle Chew is a member of the editorial board of Critical Care."

"Funding Open access funding provided by Lund University. This study was supported by grants from the Marianne and Marcus Wallenberg Foundation the Swedish Heart and Lung Foundation, the Swedish Research Council, the Bundy Academy foundation at Lund University, Skåne Region Research Funds, Malmö University Hospital Funds, the Crafoord Foundation, the Royal Physiographic Society in Lund, Swedish Research Council, Östergotland Region Research Funds, and the Ministry of Research and Education of Romania (PNRR-C9/I8-CF148)."